Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bermekimab - Janssen Biotech

Next Previous
X
Search
Drug Profile

Bermekimab - Janssen Biotech

Alternative Names: CA-18C3; CV-18C3; Human IGG1 monoclonal antibody specific for human interleukin-1 alpha; Hutruo; JNJ-77474462; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XBiotech
  • Developer Cedars-Sinai Medical Center; Hellenic Institute for the Study of Sepsis; Janssen Research & Development; XBiotech
  • Class Anti-inflammatories; Antiacnes; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma
  • Preregistration Submission Withdrawal Colorectal cancer
  • No development reported Acne vulgaris; Plaque psoriasis; Pyoderma gangrenosum
  • Discontinued Atopic dermatitis; Haematological malignancies; Hidradenitis suppurativa; Non-small cell lung cancer; Pancreatic cancer; Type 2 diabetes mellitus; Vascular restenosis

Most Recent Events

  • 01 Jan 2023 Discontinued - Phase-II for Hidradenitis suppurativa (In the elderly, In adults) in Australia, USA, Canada, Poland, Germany, Japan, Netherlands, Spain (SC)
  • 01 Jan 2023 Discontinued - Phase-II for Hidradenitis suppurativa in Greece (IV)
  • 01 Jan 2023 Discontinued - Phase-II for Hidradenitis suppurativa in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top